MUC1 and neoplasm: demonstrated that dual-target Tan CAR-T cells, targeting both MUC1 and PSCA in NSCLC and used in combination with anti-PD-1 antibody therapy, exhibit superior anti-tumor effects compared to single-target CAR-T cells, with their efficacy significantly enhanced when combined with anti-PD-1 treatment (104).